Is interleukin 3 active in anticancer drug-induced thrombocytopenia?

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 38, Issue , 1996, Pages

  Newland, Adrian C ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Dose intensification; Interleukin 3; Neutropenia; Thrombocytopenia

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 6;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0029789648     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051045     Document Type: Conference Paper

References (46)

1. Aglietta M, Sanavio F, Stacchini A, Morelli S, Fubini A (1993) Interleukin 3 in vivo: kinetic response of target cells. Blood 82: 2054
2. Biesma B, Willemse PHB, Mulder NH (1992) Effects of interleukin 3 after chemotherapy for advanced ovarian cancer. Blood 80: 1141
3. Brugger W, Bross K, Frischi J, Dem P, Weber B, Mertelsmann R, Kanz L (1992) Mobilisation of peripheral blood progenitor cells by sequential administration of interleukin 3 and granulocyte macrophage colony stimulating factor following polychemotherapy with etoposide, ifosfamide and cisplatin. Blood 79: 1193
4. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L (1995) Reconstitution of haematopoiesis after high dose chemotherapy by autologous progenitor cells generated ex-vivo. N Engl J Med 333: 283
5. Carrington PA, Hill RJ, Stenberg PE, Levin J, Covash L, Schreurs J, Baker G, Levin FC (1991) Multiple in-vivo effects of interleukin 3 and interleukin 6 on murine megakaryocytopoiesis. Blood 77: 34
6. Ceribelli A, Fossati C, Gamucci T, Tritarelli E, Testa V, Peschle C, Squotti C, Calabresi F (1992) Interleukin 3 by 120 hour continuous infusion after myelosuppressive chemotherapy: a phase 1 study. Proc Am Assoc Cancer Res 33: 231
7. Demitri GD, Young DC, Merica E, Edwards R, Pratt ES, Oldham F, Nadler P, Antman K, Griffin JD (1991) Clinical effects of interleukin 3 in patients with advanced sarcomas, a phase I/II trial. Blood 78:12
8. Dercksen MW, Hoekman K, Ten Bokkel Huinink WW, Rankin EW, Dubbelman K, Van Tinteren H, Wagstaff J, Pinedo HM (1993) Effects of interleukin 3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours. Br J Cancer 68: 996
9. De Vries EGE, Biesma B, Vellenga E, Sleijfer DT, Mulder NH, Bouma J, Mull R, Willemse PHB (1992) Recombinant human interleukin 3 for chemotherapy dose intensification in advanced ovarian cancer. Proc Am Soc Clin Oncol 11: 4230
10. D'Hondt V, Weynants P, Hamblet Y, Guillaume T, Canon JL, Beauduin M (1993) Dose dependent interleukin 3 stimulation of thrombopoiesis and neutropoiesis in patients with small cell lung carcinoma before and following chemotherapy: a placebo controlled randomised phase Ib study. J Clin Oncol 11: 2063
11. Donahue RE, Sectra J, Metzger M, Lefebvre D, Rock B, Carbone S, Nathan DG (1988) Human IL-3 and GM-CSF act synergistically in stimulating haematopoiesis in primates. Science 241: 1820
12. Fay J, Felser J, Lazasus H, Herzig R, Saez R, Stevens D, Collins R (1993) Sequential administration of interleukin 3 and rhGM-CSF following autologous bone marrow transplantation. Blood 82: 287A
13. Furman WL, Crist WM (1991) Potential uses of recombinant human granulocyte-macrophage colony-stimulating factor in children. Am J Pediatr Hematol Oncol 13: 388
14. Ganser A, Lindemann A, Seipelt G (1991) Clinical effects of recombinant human interleukin 3. Am J Clin Oncol 14: 51
15. Geissler K, Valent P, Mayer P, Liehl E, Hinterberger W, Lechner P, Bettelheim P (1990) Recombinant human interleukin 3 expands the pool of circulating hematopoietic progenitor cells in primates - synergism with rh GM-CSF. Blood 75: 2305
16. Gerhartz HH, Walther J, Bunica O, Klener P, Visani G, Peschl C, Huber W, Willmanns W, Mull R, Sklenar-T (1992) Clinical, haematological and cytokine response in interleukin 3 supported chemotherapy in resistant lymphoma: a phase II study. Proc Am Soc Clin Oncol 11: 329
17. Gianelli-Borradori A (1994) Present and future clinical relevance of interleukin 3. Stem Cells 12: 241
18. 2) cyclophosphamide cancer therapy. Ann Oncol 4: 759
19. Gillio AP, Carparetto C, Larer J, Abboud M, Bonilla MA, Garnick MB, O'Reilly RJ (1990) Effects of interleukin 3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates. J Clin Invest 85: 1560
20. Hoelzer D, Seipelt G, Ganser A (1991) Interleukin 3 alone and in combination with GM-CSF in the treatment of patients with neoplastic disease. Semin Hematol 22: 17
21. Hoffman R (1993) Interleukin 3: a potentially useful agent for treating chemotherapy related thrombocytopenia. J Clin Oncol 11: 2057
22. Hrynuik W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in ovarian cancer. J Clin Oncol 4: 1162
23. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS, Roth GJ, Papayannopoulou T, Foster DC (1994) Promotion of megakaryocyte progenitor expansion and differentiation by the C-MPL ligand thrombopoietin. Nature 369: 568
24. Kurzrock R, Estror Z, Talpaz M (1991) Interleukin 3. Am J Clin Oncol 14: 45
25. Lindemann A, Mertelsmann R (1993) Interleukin 3; structure and function. Cancer Invest 11: 609
26. Lindemann A, Ganser A, Herrmann F, Frisch J, Seipelt G, Schulz G, Hoelzer D, Mertelsmann R (1991) Biologic effects of recombinant human interleukin 3 in-vivo. J Clin Oncol 9: 2120
27. Mayer P, Valent P, Schmidt G, Liehl E, Bettelheim P (1989) The in-vivo effects of recombinant human interleukin 3. Blood 74: 613
28. Mayer RY, Davis RB, Schiffer CA, for the CLGB (1994) Intensive post remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331: 896
29. Metcalf D (1993) Haematopoietic regulators: redundancy or subtlety? Blood 82: 3515
30. Metcalf D, Begley CG, Johnson GR, Nicola NA, Lopez AF, Williamson DJ (1986) Effects of purified bacterially synthesised murine multi CSF (11-3) on haematopoiesis in normal adult mice. Blood 68: 46
31. Murray N (1987) The importance of dose and dose intensity in lung cancer chemotherapy. Semin Oncol 14 [Suppl 4]: 20
32. Nemunaitis J, Rabinowe SN, Singer JW (1991) Recombinant granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324: 1773
33. Nemunaitis J, Appelbaum FR, Singer JW (1993) Phase 1 trial with recombinant human interleukin 3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood 82: 3273
34. Newland AC (1995) The problem of thrombocytopenia and its management. Anticancer Drugs 6: 65
35. Nicola NA, Metcalf D (1991) Subunit promiscuity among hemopoietic growth factor receptors. Cell 67: 1
36. Postmus PE, Gietema JA, Damsma O (1992) Effects of recombinant human interleukin 3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. J Clin Oncol 10: 1131
37. Raemakers J, Van Imhoff G, Verdonck L, Hessels J, Fibbe W (1993) The tolerability of continuous intravenous infusion of interleukin 3 after DHAP chemotherapy in patients with relapsed malignant lymphoma: a phase 1 study. Am J Hematol 67: 175
38. Schmidtz N, Linch DC, Dreger P, Boogaerts MA, Goldstone AG, Ferrant A (1994) Phase III study of Filgrastim mobilised peripheral blood progenitor cell transplantation in comparison with autologous bone marrow transplantation in patients with Hodgkin's lymphoma. Blood 84: 204A
39. Schmidtz N, Linch DC, Dreger P, Goldstone AG, Boogaerts M, Ferrant A, Demuynck HMS, Link H, Zander A, Barge A (1996) Randomised trial of Filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 347: 386
40. Sheridan WP, Begley CG, Jutkner CA (1992) Effects of peripheral blood progenitor cells mobilised by Filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 339: 640
41. Stahl CP, Winton EF, Monroe MO (1992) Differential effects of sequential, simultaneous and single agent interleukin 3 and granulocyte macrophage colony stimulating factors in megakaryocyte maturation and platelet response in primates. Blood 80: 2479
42. Tepler I, Elias A, Young D, Levitt D, Gaynes L, Demetri G (1992) Use of recombinant human interleukin 3 after "ICE" chemotherapy for non-small cell lung cancer; effect on hematologic recovery. Proc Am Soc Clin Oncol 11: 296
43. Tepler I, Cannistra SA, Frei E III (1993) Use of peripheral blood progenitor cells abrogates myelotoxicity of repetitive out-patient high dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 1: 1584
44. Valent P, Geissler K, Sillaber C (1990) Why clinicians should be interested in interleukin 3. Blut 61: 338
45. Winton EF, Kim BK, Srinivasiah J (1992) Comparative effectiveness of rh IL-6, rh IL-3 or recombinant rh IL-6/IL3 in preventing hepsulfan induced neutropenia and thrombocytopenia in a non-human primate model. Blood 80: 90A
46. Yoshida T, Nakamura S, Ohtake S (1990) Effect of granulocyte colony stimulating factor in neutropenia due to chemotherapy for non-Hodgkin's lymphoma. Cancer 66: 1904